BACKGROUND: Elevated factor (F)XI and tissue factor (TF) have been reported to occur in patients with acute ischemic stroke (AIS). We sought to investigate whether circulating activated FXI (FXIa) and TF on admission can predict clinical outcomes in patients with acute cerebrovascular events. MATERIALS AND METHODS: In the observational study, we evaluated 205 consecutive patients aged 70 years or less within the first 72 h of acute event, including 140 with AIS and 65 with transient ischemic attack (TIA). Plasma TF and FXIa activity were determined on admission in clotting assays by measuring the response to inhibitory monoclonal antibodies. RESULTS: Active TF and FXIa activity were detected in 58 (28·9%) and 132 (64·4%) patients on admission, respectively. Active TF was detected in 45 of the 136 AIS patients with available TF levels (33·1%) and 13 of the 65 patients with acute TIA (20%; 0·05). Corresponding values for FXIa were 99 of the 140 (70·7%) and 33 of the 65 (50·8%; P= 0·006), respectively. Patients with detectable TF were more frequently women and hypertensive, while subjects with detectable FXIa had more often diabetes and higher levels of fibrinogen, C-reactive protein and interleukin-6 (all P < 0·05). Patients with detectable FXIa but not TF had higher National Institutes of Health Stroke Scale score, higher modified Rankin scale score and lower Barthel Index at discharge (all P < 0·05). CONCLUSIONS: Circulating active TF and FXIa occur frequently in acute cerebrovascular ischemic events. Active FXIa in plasma might be useful as a novel risk marker of worse functional outcomes in patients with acute cerebrovascular events.
BACKGROUND: Elevated factor (F)XI and tissue factor (TF) have been reported to occur in patients with acute ischemic stroke (AIS). We sought to investigate whether circulating activated FXI (FXIa) and TF on admission can predict clinical outcomes in patients with acute cerebrovascular events. MATERIALS AND METHODS: In the observational study, we evaluated 205 consecutive patients aged 70 years or less within the first 72 h of acute event, including 140 with AIS and 65 with transient ischemic attack (TIA). Plasma TF and FXIa activity were determined on admission in clotting assays by measuring the response to inhibitory monoclonal antibodies. RESULTS: Active TF and FXIa activity were detected in 58 (28·9%) and 132 (64·4%) patients on admission, respectively. Active TF was detected in 45 of the 136 AISpatients with available TF levels (33·1%) and 13 of the 65 patients with acute TIA (20%; 0·05). Corresponding values for FXIa were 99 of the 140 (70·7%) and 33 of the 65 (50·8%; P= 0·006), respectively. Patients with detectable TF were more frequently women and hypertensive, while subjects with detectable FXIa had more often diabetes and higher levels of fibrinogen, C-reactive protein and interleukin-6 (all P < 0·05). Patients with detectable FXIa but not TF had higher National Institutes of Health Stroke Scale score, higher modified Rankin scale score and lower Barthel Index at discharge (all P < 0·05). CONCLUSIONS: Circulating active TF and FXIa occur frequently in acute cerebrovascular ischemic events. Active FXIa in plasma might be useful as a novel risk marker of worse functional outcomes in patients with acute cerebrovascular events.
Authors: Christian Kannemeier; Aya Shibamiya; Fumie Nakazawa; Heidi Trusheim; Clemens Ruppert; Philipp Markart; Yutong Song; Eleni Tzima; Elisabeth Kennerknecht; Michael Niepmann; Marie-Luise von Bruehl; Daniel Sedding; Steffen Massberg; Andreas Günther; Bernd Engelmann; Klaus T Preissner Journal: Proc Natl Acad Sci U S A Date: 2007-04-03 Impact factor: 11.205
Authors: Christoph Kleinschnitz; Guido Stoll; Martin Bendszus; Kai Schuh; Hans-Ulrich Pauer; Peter Burfeind; Christoph Renné; David Gailani; Bernhard Nieswandt; Thomas Renné Journal: J Exp Med Date: 2006-03-13 Impact factor: 14.307
Authors: Philberta Y Leung; Sawan Hurst; Michelle A Berny-Lang; Norah G Verbout; David Gailani; Erik I Tucker; Ruikang K Wang; Owen J T McCarty; András Gruber Journal: Transl Stroke Res Date: 2012-09 Impact factor: 6.829
Authors: Anna-Luisa Thiepold; Sebastian Luger; Marlies Wagner; Natalie Filmann; Michael W Ronellenfitsch; Patrick N Harter; Anne K Braczynski; Stephan Dützmann; Elke Hattingen; Joachim P Steinbach; Christian Senft; Johannes Rieger; Oliver Bähr Journal: Oncotarget Date: 2015-06-10
Authors: Rinske Loeffen; René van Oerle; Mathie P G Leers; Johannes A Kragten; Harry Crijns; Henri M H Spronk; Hugo Ten Cate Journal: PLoS One Date: 2016-07-15 Impact factor: 3.240
Authors: Sarah Goldman; Shannon M Prior; Jan P Bembenek; Maciej Niewada; Elżbieta Broniatowska; Anna Członkowska; Saulius Butenas; Anetta Undas Journal: J Thromb Thrombolysis Date: 2017-10 Impact factor: 2.300
Authors: Elena Lipets; Olga Vlasova; Evdokiya Urnova; Oleg Margolin; Anna Soloveva; Olga Ostapushchenko; John Andersen; Fazoil Ataullakhanov; Mikhail Panteleev Journal: PLoS One Date: 2014-01-31 Impact factor: 3.240
Authors: Piotr Kusak; Danuta Czarnecka; Matthew Gissel; Krzysztof Plens; Saulius Butenas; Anetta Undas Journal: Arch Med Sci Date: 2015-11-17 Impact factor: 3.318